Goserelin EP Impurity I is a structurally related variant produced during goserelin synthesis. Differences in protecting-group removal or residue configuration influence retention time and secondary structure. Researchers employ it to validate sensitivity of analytical workflows. Applications include impurity profiling, stability studies, and peptide-route refinement.
CAT No: Z10-101-236
Synonyms/Alias:Endo-8a,8b-di-L-proline-goserelin; (S)-N-((6S,9S,12R,15S,18S,21S,24S)-21-((1H-Indol-3-yl)methyl)-1-amino-12-(tert-butoxymethyl)-6-((S)-2-((S)-2-((S)-2-(2-carbamoylhydrazine-1-carbonyl)pyrrolidine-1-carbonyl)pyrrolidine-1-carbonyl)pyrrolidine-1-carbonyl)-15-(4-hydroxybenzyl)-18-(hydroxymethyl)-25-(1H-imidazol-4-yl)-1-imino-9-isobutyl-8,11,14,17,20,23-hexaoxo-2,7,10,13,16,19,22-heptaazapentacosan-24-yl)-5-oxopyrrolidine-2-carboxamide;
Goserelin EP Impurity I is a specialized carbohydrate compound often encountered during the synthesis or analysis of goserelin, a well-known synthetic analogue of luteinizing hormone-releasing hormone (LHRH). As a structurally related impurity, it serves a critical role in the pharmaceutical and biochemical sectors, particularly in the context of quality control, research, and analytical development. Its unique molecular structure allows for the in-depth study of process impurities, degradation products, and the overall stability of peptide-based pharmaceuticals. Researchers and analytical chemists value Goserelin EP Impurity I for its ability to facilitate method validation and ensure the integrity of both active pharmaceutical ingredients and finished formulations. As a reference standard, it is indispensable for the identification, quantification, and characterization of trace-level impurities, supporting robust analytical methodologies and regulatory compliance within the research environment.
Pharmaceutical Research: In pharmaceutical research, the use of Goserelin EP Impurity I is integral to the development of advanced peptide therapeutics. By incorporating this impurity into analytical protocols, scientists can better understand the stability profile and degradation pathways of goserelin and its analogues. The presence of such impurities during forced degradation studies aids in simulating real-world storage and handling conditions, thereby allowing the identification and quantification of minor by-products that could potentially impact drug safety or efficacy. Its inclusion in research workflows enhances the ability to optimize synthetic routes and purification strategies, ultimately leading to higher-quality pharmaceutical products.
Analytical Method Development: Method development and validation require authentic reference materials to ensure specificity and accuracy. Goserelin EP Impurity I is frequently employed as a reference standard during the creation and optimization of chromatographic and spectroscopic methods, such as HPLC or LC-MS. By using this impurity, analytical chemists can establish precise retention times, confirm peak purity, and validate the sensitivity and selectivity of their assays. This process not only strengthens the reliability of impurity profiling but also supports compliance with international guidelines for impurity analysis, ensuring that pharmaceutical products meet stringent quality expectations.
Stability Studies: Stability studies are essential for determining the shelf-life and storage requirements of peptide drugs. Goserelin EP Impurity I plays a pivotal role in these investigations by serving as a marker for potential degradation products. Through accelerated stability testing, researchers can monitor the formation and progression of this impurity under various environmental conditions, such as temperature, humidity, and light exposure. The data generated provides valuable insights into the chemical behavior of goserelin formulations, enabling the refinement of packaging, storage, and handling protocols to preserve product integrity throughout its lifecycle.
Process Optimization: Process chemists rely on the detection and quantification of impurities like Goserelin EP Impurity I to evaluate and refine synthetic and purification processes. By tracking the levels of this compound at different stages of manufacturing, scientists can identify critical control points and implement targeted interventions to minimize impurity formation. This approach not only improves process efficiency but also enhances product purity and consistency, which are vital for the successful scale-up and commercialization of peptide drugs.
Reference Standard Supply: The preparation and distribution of high-quality reference materials is an essential aspect of pharmaceutical quality assurance. Goserelin EP Impurity I is supplied to research laboratories, analytical service providers, and manufacturers to support a wide range of analytical and quality control activities. Its availability ensures that laboratories have access to well-characterized impurities for routine testing, training, and proficiency assessment. The consistent use of such reference standards underpins the accuracy and reproducibility of analytical results, fostering confidence in impurity profiling and contributing to the overall advancement of pharmaceutical research and development.
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.
From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.
Read More